MOLOGEN AG
MOLOGEN AG resolves capital increase through rights issue
MOLOGEN AG / Key word(s): Capital Increase NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
– Placement of up to 5,657,875 new shares – Shareholders granted subscription rights with a 1:3 subscription ratio – Issue proceeds to be used primarily for continuing the pivotal study for the main product MGN1703 – Subscription price likely to be set on March 30, 2015 Berlin, March 24, 2015 – Today, with the agreement of the Supervisory Board, the Executive Board of biotechnology company MOLOGEN AG resolved the implementation of a capital increase against cash contributions. The company’s share capital is to be increased from EUR 16,973,626 to up to EUR 22,631,501 by issuing a total of up to 5,657,875 new shares. Subject to the relevant securities prospectus being approved by the Federal Financial Supervisory Authority (BaFin), the company’s shareholders will be offered the new shares by means of indirect subscription rights as part of an public offering in Germany and Luxembourg during a two-week subscription period. The subscription price will be set separately. The subscription ratio is one for three. This means that shareholders will be granted a subscription right to one new share for every three shares held in the company. Based on shares held by shareholders at that moment, the specified time for assignment of subscription rights is likely to be the evening of April 2, 2015, this being the likely date of publication of the subscription offer by the company. There are plans for an international private placement of any remaining shares with qualified investors in selected countries outside Germany and Luxembourg after the end of the subscription period. Dr. Matthias Schroff, Chief Executive Officer of MOLOGEN AG, explained: “The capital increase is an important milestone in the further development of our cancer immunotherapies. We are making considerable progress with our ongoing trials. Our aim is to considerably advance the pivotal study for our main product, MGN1703, using the fresh funds raised.” Setting of subscription price scheduled for March 30, 2015 Rights offering and offering prospectus Once the offering prospectus has been approved, the rights issue is likely to be announced in the Federal Gazette on April 2, 2015, a link to which will then also be available on the company’s website. MOLOGEN shareholders may only exercise their subscription right to new shares within the two week subscription period, which is currently expected to start on April 7, 2015 and end on April 21, 2015. Inclusion of the new shares under the company’s existing listing (ISIN DE0006637200/WKN 663720) is planned on April 28, 2015. This release does not constitute an offer of securities for sale in the United States of America. In the United States of America, no securities may be offered or sold absent registration or in exercise of an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). There will be no public offer of the securities in the United States of America. Subject to certain exceptions, the securities referred to herein may not be offered or sold in Australia, Canada, Japan or South Africa or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada, Japan or South Africa. This document is not for general publication, release or distribution in the United Kingdom and may only be distributed in the United Kingdom to persons who (i) are investment professionals falling within article 19(5) of the U.K. Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, in its current version (the “Order”), or (ii) are high net worth entities or other persons to whom it may lawfully be communicated within the meaning of article 49(2)(a) to (d) of the Order (each such person a “Relevant Person”). Anyone in the United Kingdom who is not a Relevant Person may not act on the basis of this document or its contents or rely thereon. Any investment or investment activity to which this document refers is only available to a Relevant Person and is only carried out with a Relevant Person. MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. For more information on the trials please visit: www.clinicaltrials.gov. With unique, patented technologies and innovative products, MOLOGEN is pioneering immunotherapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
2015-03-24 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
337021 2015-03-24 |